Scientists have discovered that a small chemokine protein released by activated platelets, platelet factor 4 (PF 4), reduced neuroinflammation, and improved cognition in aged mice. The study was published on Aug. 16 in the online edition of Nature. Read More
Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies. Read More
Day One Biopharmaceuticals Inc. has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience... Read More
Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked... Read More
Approximately 100 years ago, Otto Warburg discovered that glucose consumption is elevated over ten-fold in cancer cells compared to normal... Read More
Alcohol use disorder (AUD) refers to a medical condition, considered a brain disorder, where individuals are unable to stop drinking alcohol... Read More
Interleukin-4 (IL-4) plays an important role in regulating inflammation. While several antibody-based options targeting IL-4 have been reported, strategies based on small molecule inhibitors have proven difficult to find. Read More
Terran Biosciences Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of anxiety, Alzheimer's disease, stroke, rheumatoid arthritis, neurodegeneration, mood disorders, menopause, substance abuse and dependence, among others. Read More
Novartis AG has identified spirocyclic piperidinyl derivatives acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration (AMD), diabetic retinopathy and eye disorders. Read More
Artiva Biotherapeutics Inc. has received FDA clearance of its IND application for Allonk (AB-101), to be used in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis. Read More
Cgenetech (Suzhou, China) Co. Ltd. has divulged cyclopropanamide-containing compounds acting as Janus kinase (JAK) inhibitors, particularly JAK2 and/or JAK1 and/or JAK3, reported to be useful for the treatment of rheumatoid arthritis, ulcerative colitis, atopic dermatitis, systemic lupus erythematosus, essential thrombocythemia, polycythemia vera and myelofibrosis. Read More
Oncusp Therapeutics Inc. has received IND clearance from the FDA to begin clinical trials with CUSP-06, a cadherin-6 (CDH6)-targeting antibody-drug conjugate designed for the treatment of multiple solid tumors. CDH6 is overexpressed in cancers including ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma. A phase I trial will pave the way for expansion in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. Read More
Researchers from Shandong University and colleagues presented the characterization of [I] as the most active compound from a series of novel diarypyridimine derivatives intended to overcome resistance to NNRTI-resistant HIV-1 strains. The compound displayed EC50 values of 0.0010 and 0.18 µM against HIV IIIB and RES056 strains, respectively. Read More
